45—armata new cocktail!

Armata Pharmaceuticals has developed a new synthetic phage candidate targeting P. aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The cocktail, a mixture of synthetic and natural phages, has been elevated to the lead clinical candidate in their pipeline, and clinical trials to test its efficacy are being planned in both the US and Europe.